Vistagen Social Anxiety Treatment Phase 3 Trial Results Coming Q4 2025

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today provides an update on the timeline for the ongoing clinical trials in its U.S. registration-directed PALISADE Phase 3 Program evaluating fasedienol for acute treatment of social anxiety disorder (SAD). The Company’s PALISADE-3 Phase 3 clinical trial remains on track for expected topline data in the fourth quarter of this year. Topline results for its PALISADE-4 Phase 3 clinical trial are expected in the first half of 2026.

https://www.stocktitan.net/news/VTGN/vistagen-on-track-to-deliver-topline-data-from-fasedienol-palisade-3-6r9vbji5v7h9.html